Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

BACKGROUND: Dual-targeted anti-HER2 therapy significantly improves outcomes in HER2-positive breast cancer and could be beneficial in other HER2-positive cancers. JACOB’s end-of study analyses aimed to evaluate the long-term efficacy and safety of pertuzumab plus trastuzumab and chemotherapy for pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Hoff, Paulo M., Shen, Lin, Ohtsu, Atsushi, Shah, Manish A., Siddiqui, Asna, Heeson, Sarah, Kiermaier, Astrid, Macharia, Harrison, Restuccia, Eleonora, Kang, Yoon-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813086/
https://www.ncbi.nlm.nih.gov/pubmed/36066725
http://dx.doi.org/10.1007/s10120-022-01335-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813086/
https://www.ncbi.nlm.nih.gov/pubmed/36066725
http://dx.doi.org/10.1007/s10120-022-01335-4

Ejemplares similares